Ligand Pharmaceuticals buying Xoma Royalty for $739 million

The royalty aggregator model, which some companies use, involves taking stakes successful drugs that are inactive successful objective improvement and earning royalty payments connected income if those treatments yet triumph approval. The woody would grow Ligand's royalty portfolio to much than 200 assets and adhd 7 commercialized products, the institution said.

Xoma stockholders volition besides person 1 non-transferable Contingent Value Right per share, entitling them to a information of 75% of immoderate nett proceeds from ongoing litigation involving Xoma's quality with Janssen Biotech implicit the commercialization of TREMFYA. The currency connection represents a premium of astir 14% to Xoma's 30-day measurement weighted mean terms arsenic of April 24, 2026, the past trading time earlier the announcement. Ligand banal was up astir 3.9% successful premarket trading connected the time of the announcement, according to The Wall Street Journal.

Ligand volition money the acquisition utilizing existing currency and borrowings nether its existing recognition facility, the institution said. The transaction has been unanimously approved by some boards of directors. Entities affiliated with BVF Partners, which clasp astir 21% of Xoma's outstanding communal stock, person entered into a voting statement supporting the deal.

Among the assets Ligand gains done the acquisition are royalty interests successful Roche's oculus attraction Vabysmo, Day One Pharmaceuticals' brain-cancer cause Ojemda, and Zevra Therapeutics' Miplyffa, arsenic good arsenic 14 programs successful late-stage development.

"This acquisition volition adhd 7 marketed products and astir treble our portfolio of Phase 2 and 3 assets," Ligand CEO Todd Davis said successful a statement. Davis added that the woody would let Ligand to turn successful areas specified arsenic ophthalmology, oncology, CNS, and uncommon diseases.

Xoma CEO Owen Hughes said successful a connection that the woody "delivers to our stockholders some the intrinsic worth of XOMA's portfolio contiguous and the optionality associated with our ongoing litigation with Janssen Biotech via the CVR."

For full-year 2026, Ligand updated its gross outlook to $270 cardinal to $310 million, compared with its earlier forecast of $245 cardinal to $285 million. The institution besides accrued its 2026 adjusted net per diluted stock guidance to $8.50 to $9.50, from $8.00 to $9.00. Ligand said it expects the transaction to adhd $1.50 per stock to adjusted net per stock successful 2027.

The woody is expected to adjacent successful the 3rd 4th of 2026, taxable to support by Xoma stockholders and receipt of definite regulatory approvals.